MERLIN NEXUS
Merlin Nexus, based in New York, is a company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies. With its first fund launched in 2001 by Dominique Sémon, Merlin Nexus now has several crossover private equity funds and a public-only fund, with commitments totaling over $175 million. Currently, the Merlin Nexus team consists of 5 investment professionals. Their varied healthcare backgrounds... provide broad industry knowledge spanning later-stage biotechnology, specialty pharmaceuticals and medical devices. It has later-stage investment focus as compared to traditional venture capital firms and invests opportunistically and selectively. The company's investor base consists of financial institutions, funds of funds, family offices and high net worth individuals.
MERLIN NEXUS
Founded:
2001-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Apache Network Solutions DNS Symantec Secure Site Confluence Networks Intermedia
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-01-08 | Zymeworks | Merlin Nexus investment in Series A - Zymeworks | 61.5 M USD |
| 2014-09-25 | Adaptimmune | Merlin Nexus investment in Series A - Adaptimmune | 104 M USD |
| 2013-12-16 | Stem Cell Therapeutics | Merlin Nexus investment in Post-IPO Equity - Stem Cell Therapeutics | 33 M USD |
| 2011-05-31 | WaferGen Biosystems | Merlin Nexus investment in Post-IPO Equity - WaferGen Biosystems | 30 M USD |
| 2009-04-07 | Sunesis Pharmaceuticals | Merlin Nexus investment in Post-IPO Equity - Sunesis Pharmaceuticals | 43.5 M USD |
| 2008-10-03 | Micromet | Merlin Nexus investment in Post-IPO Equity - Micromet | 40 M USD |
| 2007-10-25 | Xencor | Merlin Nexus investment in Series E - Xencor | 15 M USD |